Exhibit 99.1
Press Release | |
www.shire.com | |
Holding(s) in Company
March 16, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG)
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii | Shire plc |
2 Reason for the notification(please tick the appropriate box or boxes): |
An acquisition or disposal of voting rights | X |
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |
An event changing the breakdown of voting rights | |
Other (please specify): | | |
3. Full name of person(s) subject to the notification obligation: iii | Harbor International Fund (a series of Harbor Funds, a Delaware Statutory Trust) |
4. Full name of shareholder(s) (if different from 3.):iv | |
5. Date of the transaction and date on which the threshold is crossed or reached:v | Trade Date: March 9, 2016 Settlement Date: March 11, 2016 |
6. Date on which issuer notified: | March 15, 2016 |
7. Threshold(s) that is/are crossed or reached:vi, vii | 3% of issuer’s voting rights |
| | | | |
8. Notified details: |
A: Voting rights attached to sharesviii, ix |
Class/type of shares if possible using the ISIN CODE
| Situation previous to the triggering transaction | Resulting situation after the triggering transaction |
Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rightsx |
Direct | Directxi | Indirectxii | Direct | Indirect |
Common SEDOL: B2QKY05 | 17,591,183 | 17,591,183 | 17,936,613 | 17,936,613 | N/A | 3.03% | N/A |
|
|
B: Qualifying Financial Instruments |
Resulting situation after the triggering transaction |
Type of financial instrument | Expiration datexiii | Exercise/ Conversion Periodxiv | Number of voting rights that may be acquired if the instrument is exercised/ converted. | % of voting rights |
N/A | N/A | N/A | N/A | N/A |
|
C: Financial Instruments with similar economic effect to Qualifying Financial Instrumentsxv, xvi |
Resulting situation after the triggering transaction |
Type of financial instrument | Exercise price | Expiration datexvii | Exercise/ Conversion periodxviii | Number of voting rights instrument refers to | % of voting rightsxix, xx |
N/A | N/A | N/A | N/A | N/A | Nominal | Delta |
N/A | N/A |
|
Total (A+B+C) |
Number of voting rights | Percentage of voting rights |
17,936,613 | 3.03% |
| | | | | | | | | | | | | | | | | |
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:xxi |
N/A |
|
Proxy Voting: |
10. Name of the proxy holder: | N/A |
11. Number of voting rights proxy holder will cease to hold: | N/A |
12. Date on which proxy holder will cease to hold voting rights: | N/A |
|
13. Additional information: | Completed in Chicago, Illinois, USA
on March 15, 2016 |
14. Contact name: | Jodie L. Crotteau Assistant Secretary |
15. Contact telephone number: | 312-443-4428 |
| | |
For further information please contact:
Investor Relations | | |
Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com